TORONTO, Oct. 4, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX:
KHRNF)(Frankfurt: A2JMZC), a
vertically integrated international cannabis leader with core
operations in Latin America and
Europe, is pleased to provide a
corporate update on global medical cannabis operations:
Medical Cannabis
Latin America
- Medical cannabis prescriptions grew by more than 40%, from Q2
2021
- Year to date medical cannabis prescriptions have exceeded
35,000 units, 600% more than the entire 2020 fiscal year
- Total medical cannabis patients in Q3 increased to more than
9,600, up 32% from Q2 2021
- 62% of the patients in Q3 were returning patients, up 35% from
Q2 2021
- 47% of units sold were covered by insurance
- New satellite clinics accounted for 10% of prescriptions
Europe
- Europe generated 30% of the
Company's medical cannabis sales in Q3 2021
- Germany revenues expected to
grow more than 80% and UK revenues expected to grow more than 70%
quarter on quarter
- The Company has increased its imported volumes in the U.K.,
ensuring uninterrupted supply for all Khiron patients
Health Services
- Year to date patient visits at Khiron clinics have exceeded
104,000, topping all patient visits in 2020
- Revenue in health services is steadily returning to normal at
Zerenia clinics as pandemic measures ease
- Total quarterly patient visits at Zerenia were up 18% quarter
on quarter
- Khiron will expand its flagship clinic brand, Zerenia to the
UK, with the first Zerenia opening in London in Q4 2021.
Management Commentary
"Through the end of Q3, the
Company continued to make steady progress in helping more patients
access medical cannabis. Europe is
starting to become an important market for the Company, and we will
soon be opening our first Zerenia medical cannabis clinic in the
UK. Our integrated clinic model continues to connect
patients, doctors, and insurance, helping improve patient
outcomes. The integrated medical clinic approach offers a
range of treatments and services, including medical cannabis, that
help patients save time and money by not having to travel to seek
out individual treatments. Almost half of our patients
have insurance coverage now, a tremendous improvement since our
first covered prescription in December of 2020. ", commented
Alvaro Torres, Chief Executive
Officer and Director of the Company.
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated international medical cannabis company with
core operations in Latin America
and Europe. Leveraging
wholly-owned medical health clinics and proprietary telemedicine
platforms, Khiron combines a patient-oriented approach, physician
education programs, scientific expertise, product innovation, and
agricultural infrastructure to drive prescriptions and brand
loyalty with patients worldwide. The Company has a sales presence
in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Linkedin at
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-reports-medical-cannabis-prescription-growth-in-south-america-and-europe-301391489.html
SOURCE Khiron Life Sciences Corp.